A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

NCT05245344 ·Status: UNKNOWN

A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis

NCT06588387 ·Status: COMPLETED

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

NCT05605782 ·Status: ACTIVE_NOT_RECRUITING

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

NCT01628393 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition

NCT02598167 ·Status: COMPLETED

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

NCT02047734 ·Status: COMPLETED ·Phase: PHASE3

A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice

NCT06251986 ·Status: COMPLETED

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

NCT01185821 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

NCT06396039 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants

NCT06133049 ·Status: ACTIVE_NOT_RECRUITING

Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS

NCT06334094 ·Status: WITHDRAWN ·Phase: PHASE4

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

NCT04140305 ·Status: TERMINATED ·Phase: PHASE3

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

NCT06408259 ·Status: RECRUITING ·Phase: PHASE3

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02861014 ·Status: COMPLETED ·Phase: PHASE3

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

NCT00097331 ·Status: COMPLETED ·Phase: PHASE2

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

NCT01665144 ·Status: COMPLETED ·Phase: PHASE3

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

NCT06529406 ·Status: RECRUITING ·Phase: PHASE4

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT02776072 ·Status: COMPLETED

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

NCT07299019 ·Status: RECRUITING ·Phase: PHASE3

Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

NCT05776888 ·Status: ACTIVE_NOT_RECRUITING

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients

NCT01895335 ·Status: COMPLETED ·Phase: PHASE4

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

NCT02430532 ·Status: TERMINATED ·Phase: PHASE3

Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis

NCT02035514 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse

NCT00753792 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

NCT05147220 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3